胃癌靶向治疗的研究进展  

Research progress in targeted therapy for gastric cancer

作　　者：潘旭红 马未节 邵香香 王永英 李红玲[2] PAN Xu-hong;MA Wei-jie;SHAO Xiang-xiang;WANG Yong-ying;LI Hong-ling(Clinical Medical College of Gansu University of Traditional Chinese Medicine,Lanzhou 730000;Department of Oncology,Gansu People’s Hospital,Lanzhou 730000)

机构地区：[1]甘肃中医药大学第一临床医学院,兰州730000 [2]甘肃省人民医院肿瘤科,兰州730000

出　　处：《中南药学》2023年第3期735-741,共7页Central South Pharmacy

基　　金：国家自然科学基金项目(No.81760537,No.81560498);甘肃省科技厅国际合作项目(No.20YF8WA096);甘肃省人民医院院内项目(No.19SYPYA-3);甘肃省优秀研究生“创新之星”项目(No.2021CXZX-737)。

摘　　要：胃癌是最常见的消化系统恶性肿瘤,严重威胁人类健康。其发病与幽门螺杆菌感染、遗传、高亚硝酸盐饮食、癌前病变等多种因素相关。早期胃癌发病隐匿,诊断率低(约10%),同时缺乏治疗和预后相关的生物学标志物,治疗预后不佳,患者的中位生存期较短。近年来随着对癌基因序列、发病机制的深入研究,基于基因的靶向精准医疗成为胃癌尤其是晚期及复发癌治疗的新模式。分子靶向治疗不仅能提高抗癌疗效的特异性,同时能降低非选择性耐药和毒性作用。本文将对胃癌靶向治疗分子机制及最新的临床试验研究作一综述,以期为胃癌的治疗提供更好的帮助。Gastric cancer is the most common malignant tumor of the digestive system,which seriously threatens human health.Its incidence is related to helicobacter pylori infection,genetics,high nitrite diet,precancerous lesions and other factors.Early gastric cancer has insidious onset,and low diagnostic rate(about 10%),lacks treatment and prognosis related biomarkers,and result in poor prognosis and short median survival of patients.In recent years,with the in-depth study of oncogene sequence and pathogenesis,gene-based targeted precision medicine has become a new model in the treatment of gastric cancer,especially advanced and recurrent cancer.Molecular targeted therapy not only improves the specificity of anticancer efficacy,but also reduces non-selective drug resistance and toxicity.This article reviewed the molecular mechanism of targeted therapy for gastric cancer and the latest clinical trials to provide better help for gastric cancer。

关 键 词：胃癌 靶向治疗 分子机制 研究进展 

分 类 号：R735.2[医药卫生—肿瘤] R97[医药卫生—临床医学]